Test Price
2,800 AED✅ Home Collection Available
PMS2 Gene Genetic Test for Lynch Syndrome in UAE | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Next‑Generation Sequencing, validated by Sanger confirmation.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary telehealth post‑test clinical interpretation by a certified genetic counsellor or oncologist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The PMS2 gene test identifies germline mutations responsible for Lynch syndrome (hereditary non‑polyposis colorectal cancer) and constitutional mismatch repair deficiency, guiding personalised cancer surveillance and prophylactic interventions. The analysis is clinically validated for whole blood, extracted DNA, or FTA card samples and must be preceded by genetic counselling.
| Feature | Our Test (PMS2 NGS) | Closest Alternative |
|---|---|---|
| Diagnostic Sensitivity | 99.9% (NGS + Sanger confirmation) | ~95% (Single‑gene Sanger) |
| Methodology | Full‑gene NGS, ACMG variant classification, MLPA for large rearrangements | Conventional Sanger sequencing, limited CNV detection |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Pre‑test Support | Complimentary genetic counselling session | Often not included |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA 9294403)
“A PMS2 result is a powerful risk assessment tool, not a cancer diagnosis. It must always be interpreted alongside the patient’s family history and clinical presentation. I emphasise that a variant of uncertain significance does not equate to disease, and ongoing reclassification ensures the highest accuracy. Even a negative result does not eliminate all hereditary risk, so standard cancer screening should continue.”
Medication & Safety Advisory
Patients should not stop prescribed medications or cancer prevention therapies without direct supervision from their treating physician. Genetic test results supplement, but never replace, routine clinical care and surveillance.
Exclusion Criteria & Emergency Red Flags
- Patients unable to give informed consent or without a legal guardian, as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Active haematological malignancy that may interfere with DNA extraction from blood (an alternative tissue source must be arranged).
- Emergency Red Flags: sudden severe abdominal pain, unexplained rectal bleeding, or jaundice with weight loss – seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. Who should consider PMS2 genetic testing?
Individuals with a personal or family history of colorectal or endometrial cancer before age 50 should undergo PMS2 analysis. Additional candidates include those with multiple Lynch‑spectrum cancers in the family, confirmed Lynch syndrome in a relative, or tumours showing microsatellite instability. Testing is also offered to asymptomatic adults seeking risk clarification, but it must be preceded by genetic counselling.
2. How is the test performed and what samples are accepted?
A simple blood draw, extracted DNA, or a dried blood spot on an FTA card is all that is required. Our phlebotomy team collects a venous blood sample in an EDTA tube following cold‑chain protocols, or you can provide pre‑extracted DNA. No fasting is necessary. The sample is sequenced with high‑coverage NGS, and pathogenic variants are confirmed by Sanger sequencing according to ACMG/AMP guidelines.
3. What does a positive or negative result mean for my future health?
A positive result confirms hereditary Lynch syndrome, enabling life‑saving surveillance and risk‑reducing strategies, but it is not a cancer sentence. You will be offered a personalised surveillance plan (colonoscopy every 1–2 years, endometrial screening, etc.) and family cascade testing. A negative result significantly lowers your Lynch syndrome risk but does not eliminate sporadic cancer possibilities; routine screening remains essential. Variants of unknown significance are actively studied and reclassified over time.
UAE Regulatory & Data Privacy Adherence
Data Protection & Clinical Compliance
All genetic data handling strictly complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory operates under DHA Facility License No. 1143 and maintains ISO 9001:2015 certification.
Clinical & Logistical Metadata
| Test Name | PMS2 Gene Genetic Test for Lynch Syndrome |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or Extracted DNA or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger Confirmation, MLPA for Large Rearrangements, ACMG Variant Classification |
| ICD-10-CM Code | Z15.09 (Genetic susceptibility to malignant neoplasm of other digestive organs) |
| LOINC Code | 21669-3 (PMS2 gene mutation detection by sequencing) |
| DHA Facility License & Address | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | License No. 1143 |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians